…
BioNeutra Global Corporation engages in the research and development, production, and commercialization of food for nutraceutical, functional, and mainstream food and beverage products with a focus on oligosaccharides. The company offers isomalt oligosaccharide ingredients under the VitaFiber brand for human digestive health. It operates in Canada, the United States, Australia, New Zealand, European Union, and the Asia Pacific. The company is headquartered in Vancouver, Canada.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Public filings for BioNeutra Global Corporation (Pink: BGACF) are limited, and the company's current operating activities and product lines are not well documented in publicly available sources. Given the sparse disclosure, long-term growth drivers are unclear, though investors may find exposure to a small-cap company with potential upside if commercial activities scale or transparency improves.
Key investment risks include very limited disclosure and reporting, thin market liquidity, operational and regulatory uncertainty, and heightened share-price volatility associated with Pink-listed microcap issuers.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Income before tax | -2.11M | -2.92M | -2.83M | -3.77M | -13.02M |
| Net income | -2.11M | -2.92M | -2.83M | -3.71M | -12.44M |
| Selling general administrative | 3.73M | 3.78M | 4.49M | 5.43M | 8.38M |
| Selling and marketing expenses | 0.39M | 0.14M | 0.43M | 0.36M | 0.81M |
| Gross profit | 4.14M | 2.35M | 2.89M | 3.94M | 0.64M |
| Reconciled depreciation | 1.07M | 1.11M | 1.32M | 1.84M | 2.32M |
| Ebit | -1.41M | -2.47M | -2.44M | -3.34M | -9.83M |
| Ebitda | -0.35M | -1.36M | -1.12M | -1.50M | -7.51M |
| Depreciation and amortization | 1.06M | 1.11M | 1.32M | 1.84M | 2.32M |
| Operating income | -0.89M | -2.47M | -2.35M | -3.02M | -9.83M |
| Other operating expenses | 12.27M | 15.86M | 17.76M | 27.14M | 47.53M |
| Interest expense | 0.70M | 0.45M | 0.39M | 0.43M | 0.60M |
| Tax provision | 0.00M | 0.00M | -0.00M | -0.06M | -0.58M |
| Interest income | 0.01M | 0.00M | 0.00M | 0.00M | 0.00M |
| Net interest income | -0.65M | -0.45M | -0.39M | -0.43M | -0.59M |
| Income tax expense | -1.10M | 0.45M | 0.39M | -0.06M | -0.58M |
| Total revenue | 11.38M | 13.39M | 15.40M | 24.12M | 37.70M |
| Total operating expenses | 4.14M | 4.82M | 5.25M | 6.97M | 10.47M |
| Cost of revenue | 7.24M | 11.04M | 12.51M | 20.17M | 37.06M |
| Total other income expense net | -1.22M | -0.50M | -0.47M | -0.75M | -2.59M |
| Net income from continuing ops | -4.71M | -2.92M | -2.83M | -3.71M | -12.44M |
| Net income applicable to common shares | - | - | -2.83M | -3.71M | -12.44M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 15.77M | 19.78M | 21.08M | 23.68M | 34.02M |
| Intangible assets | 0.32M | 0.43M | 0.40M | 0.64M | 1.13M |
| Other current assets | 0.57M | - | - | - | - |
| Total liab | 21.96M | 23.54M | 22.12M | 22.98M | 29.27M |
| Total stockholder equity | -6.19M | -3.76M | -1.03M | 0.70M | 4.75M |
| Other current liab | 1.39M | - | 1.10M | 1.12M | 1.37M |
| Common stock | 7.55M | - | 7.55M | 7.55M | 7.55M |
| Capital stock | 7.55M | 7.55M | 7.55M | 7.55M | 7.55M |
| Retained earnings | -16.05M | -13.95M | -11.02M | -8.19M | -4.49M |
| Other liab | - | - | - | 0.03M | 0.06M |
| Cash | 1.89M | 0.72M | 0.84M | 0.93M | 0.52M |
| Total current liabilities | 14.78M | 16.91M | 15.78M | 16.61M | 22.53M |
| Current deferred revenue | 0.05M | - | - | - | - |
| Net debt | 5.75M | 6.11M | 6.05M | 6.14M | 7.06M |
| Short term debt | 0.46M | - | - | - | - |
| Short long term debt | 0.38M | 0.30M | 0.55M | 0.74M | 0.90M |
| Short long term debt total | 7.64M | - | - | - | - |
| Other stockholder equity | 1.81M | - | 1.12M | 0.02M | 0.55M |
| Property plant equipment | - | - | 9.75M | 10.59M | 12.26M |
| Total current assets | 6.97M | 9.71M | 10.93M | 12.45M | 20.64M |
| Long term investments | - | - | - | - | 0.00M |
| Net tangible assets | - | - | -1.43M | 0.06M | 3.63M |
| Short term investments | 0.00M | - | - | - | - |
| Net receivables | 1.22M | 1.04M | 1.73M | 1.64M | 3.30M |
| Long term debt | 7.16M | 6.53M | 6.34M | 6.33M | 6.68M |
| Inventory | 3.29M | 7.18M | 8.02M | 7.85M | 14.81M |
| Accounts payable | 12.93M | 15.43M | 14.12M | 14.75M | 20.26M |
| Accumulated other comprehensive income | 0.50M | - | - | - | - |
| Non current assets total | 8.79M | 10.07M | 10.15M | 11.23M | 13.39M |
| Capital lease obligations | 0.10M | 0.18M | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | 0.01M | -0.20M | -0.28M | -0.03M | 0.28M |
| Change to liabilities | - | - | -0.65M | -5.39M | 7.94M |
| Total cashflows from investing activities | - | - | -0.28M | -0.03M | 0.28M |
| Net borrowings | - | - | 0.05M | -0.51M | -1.38M |
| Total cash from financing activities | 0.45M | -0.31M | -0.30M | -0.90M | -1.66M |
| Change to operating activities | - | - | 1.68M | -0.39M | -0.41M |
| Net income | -2.11M | -2.92M | -2.83M | -3.71M | -12.44M |
| Change in cash | 1.17M | -0.12M | -0.09M | 0.41M | -0.97M |
| Begin period cash flow | 0.72M | 0.84M | 0.93M | 0.52M | 1.50M |
| End period cash flow | 1.89M | 0.72M | 0.84M | 0.93M | 0.52M |
| Total cash from operating activities | 0.68M | 0.84M | 0.27M | 1.43M | 0.71M |
| Issuance of capital stock | - | - | - | 0.00M | 0.25M |
| Depreciation | 1.06M | 1.11M | 1.32M | 1.84M | 2.32M |
| Other cashflows from investing activities | - | - | - | - | 0.52M |
| Dividends paid | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change to inventory | 3.89M | 0.84M | -0.17M | 6.96M | -1.74M |
| Change to account receivables | -0.12M | 0.63M | -0.09M | 1.66M | 0.64M |
| Other cashflows from financing activities | -0.66M | -0.44M | -0.35M | -0.39M | -0.53M |
| Change to netincome | - | - | 1.00M | 0.46M | 0.10M |
| Capital expenditures | 0.02M | 0.20M | 0.28M | 0.08M | 0.24M |
| Change in working capital | 1.70M | 2.44M | 0.78M | 2.84M | 10.72M |
| Stock based compensation | - | 0.00M | 0.48M | 0.00M | 0.01M |
| Other non cash items | 0.04M | 0.21M | 0.52M | 0.46M | 0.52M |
| Free cash flow | 0.66M | 0.63M | -0.01M | 1.36M | 0.47M |
Sector: Consumer Defensive Industry: Packaged Foods
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BGACF BioNeutra Global Corporation |
- -% |
0.01 | - | - | 0.02 | - | 1.00 | 11.23 |
| NSRGF Nestle SA |
- -% |
99.03 | 26.86 | 18.76 | 3.13 | 7.10 | 3.81 | 21.70 |
| NSRGY Nestle SA ADR |
0.85 0.85% |
101.06 | 26.82 | 18.66 | 3.18 | 7.07 | 3.81 | 21.70 |
| DANOY Danone PK |
-0.03 0.20% |
14.93 | 24.23 | 17.64 | 1.88 | 2.57 | 1.88 | 11.70 |
| GPDNF Danone S.A |
- -% |
74.00 | 20.30 | 14.75 | 1.65 | 2.24 | 1.76 | 10.92 |
BioNeutra Global Corporation engages in the research and development, production, and commercialization of food for nutraceutical, functional, and mainstream food and beverage products with a focus on oligosaccharides. The company offers isomalt oligosaccharide ingredients under the VitaFiber brand for human digestive health. It operates in Canada, the United States, Australia, New Zealand, European Union, and the Asia Pacific. The company is headquartered in Vancouver, Canada.
| Name | Title | Year Born |
|---|---|---|
| Dr. Jianhua Zhu Ph.D. | Founder, CEO, Pres & Director | NA |
| Mr. Yiyuan Jiang | Chief Financial Officer | NA |
| Mr. Ross Montagano | Chief Operating Officer | NA |
| Vinti Goel Ph.D. | VP of Scientific & Regulatory Affairs | NA |
| Sheri O'Brien | VP of Sales & Marketing | NA |
| Monica Barclay | Corp. Sec. | NA |
| Dr. Jianhua Zhu Ph.D. | Founder, CEO, President & Director | NA |
| Dr. Stephen C. Jakeway Ph.D. | Chief Operating Officer | NA |
| Vinti Goel Ph.D. | Vice President of Scientific & Regulatory Affairs | NA |
| Mr. Dario Mejia | Vice President of Sales & Business Development | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.